GLP-1 Receptor Agonist Exposure Linked to Earlier Sequential NAION

Database Study Examines Timing of Second-Eye Optic Nerve Events

Patients diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION) who take glucagon-like peptide-1 (GLP-1) receptor agonists may experience sequential events in their second eye sooner than nonusers. Research presented at the annual meeting of the American Academy of Ophthalmology (AAO) in New Orleans evaluated records from more than 22,000 patients with a history of the condition.

Ashley Tin and colleagues from the Carle Illinois College of Medicine in Urbana conducted the analysis. The team compared individuals who took a GLP-1 receptor agonist against those who did not, focusing on the timing between optic nerve events across both eyes.

Early Event Concentration Higher among Medication Users

The researchers compared early events occurring between one and six months against late events occurring between 36 and 60 months. The dataset included 1,440 GLP-1 receptor agonist users and 20,713 nonusers, stratified by pre-era and post-era availability of these medications.

Among patients who developed sequential NAION, 69.5% of events in the medication group occurred within six months. In contrast, 52% of events in the nonuser group took place within that early window. This difference represented a relative risk of 2.63 for earlier presentation.

Differences in Blood Sugar Levels between Study Cohorts

The investigators noted that the patterns remained consistent across pre-medication and post-medication eras. This consistency matched initial clinical observations that led the researchers to run the database review.

The analysis also recorded differences in metabolic markers between the two cohorts. Patients taking GLP-1 receptor agonists presented with higher average hemoglobin A1c levels than those in the nonuser group.

Study Limitations and Clinical Considerations

This research relies on an observational database analysis and does not prove that GLP-1 receptor agonists directly cause earlier second-eye nerve events. Retrospective coding data cannot control for every clinical variable or confirm complete medication adherence.

Patients managing diabetes or weight with a GLP-1 receptor agonist who have had an episode of NAION in one eye should discuss eye risks with their ophthalmologist. Clinicians can weigh individual vascular risk factors and glycemic targets before making any medication adjustments.